Stockreport

DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial [Yahoo! Finance]

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF Early results support continued development of DS-3939, a potential first-in-class TA-MUC1 directed antibody drug conjugate TOKYO & BASKING RIDGE, N.J., October 19, 2 [Read more]